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Article Information  ABSTRACT 
Received: 14th December 2017  The emergence of microbial contaminants in non-sterile drugs caused not only the degradation of 
many products, but also proved to be a potential risk to consumer health. The aim of this study 
was to test microbial load of non sterile solid pharmaceutical product and investigate the effects 
of different packaging system on microbial status of pharmaceutical product. A total of 18 
sample of solid dosage form packaged in different packaging were procured from market. All 
samples have been tested for the presence of specific microorganisms, Total aerobic microbial 
counts (TAMC) and Total yeast and mold counts (TYMC) using compendial procedures. Out of 
18 sample 72.22 % (n=13) had shown microbial growth and only 16 % (n=3) of samples were 
non-compliant. Sample containing herbal ingredients, were the most heavily contaminated, 
showing a bacterial load > 104 CFU/g. The result showed that all the tested samples were free 
from E. coli. There was no significant difference (p>0.05) in microbial load of product packaged 
in different primary packaging. 
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INTRODUCTION 
Microbial contamination is a common quality issue with 
pharmaceutical product, which has been raised by regulatory 
authorities. Products that are contaminated with 
microorganisms are withdrawal from the market and cause 
massive financial losses to the manufacturer. A product may 
also be withdrawn if it is proven that a discrepancy has 
occurred during its manufacture or distribution, which poses a 
potential risk to public health [1]. The US Food and Drug 
Administration had announced a recall of 642 products because 
of microbial contamination, from 2004 to 2011 [2]. Recently, 
microbial burden of non-sterile pharmaceutical product get an 
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attention because of change in formulations, manufacturing and 
marketing of non sterile drugs, and the introduction of many 
new ingredients in these types of pharmaceutical preparations 
[3]. The microbial contamination of the product not only makes 
them dangerous from the infectious point of view, it can also 
change the chemical, physical and organoleptic properties of 
the medicines or change the content of the active ingredients. 
In addition, microorganisms can convert medicines into toxic 
products [4].  
The microbiological specifications, the criteria & methodology 
for microbial examination of non-sterile products are 
established and updated in the continuous editions of the 
European Pharmacopoeia (EP). Manufacturers should assure 
that the microbiological status of finished products is meet with 
acceptable criteria and free from potentially harmful organisms. 
This is achieved through the implementation of the current 
guidelines for Good Manufacturing Practices (GMPs) during 
the production, storage and distribution of these products [3].  
The methods used and the results obtained must meet the 
specifications and criteria set out in the relevant 
pharmacopoeia. Tests for total antimicrobial counts (TAMC) 
and total counts of yeasts and molds (TYMC), as well as 
identification tests for the different microorganisms were 
performed on both ingredients and end products [5]. 
 
The Indian pharmaceutical market is the third largest in terms 
of volume and thirteenth in terms of value, and represents 20% 
in volume and 1.4% in value of the global pharmaceutical 
industry, according to a report by Equity Master. India is the 
world's largest supplier of generic drugs and account for 20% 
of world output by volume. The Indian manufacturer is often 
confronted with problems in the context of market complaints 
or the adverse effects of oral drug use [6]. 
Packaging is an important factor in maintaining the quality of 
the product and maintaining its properties until the end of its 
shelf life. Considering the variety of the packaging available 
today, it is of great interest the study of the relationship 
between the drug itself and the pack-aging material used, with 
the target to the unveil  potential microorganism contamination 
[7]. The aim of this study was to evaluate microbiological 
status of non sterile solid pharmaceutical product and 
investigate the effects of different packaging system on 
microbial status of pharmaceutical product. 
 
Table 1: Microbiological Quality of Non Sterile Solid Pharmaceutical Product 
Route of administration  
TAMC 
(CFU/g) 
TYMC 
(CFU/g) 
Specified micro-organism 
Non-aqueous preparations for oral use 10
3 102 Absence of Escherichia coli (1 g) 
Oral dosage forms containing raw 
materials of natural origin 
104 102 
Absence of Escherichia coli (1 g) 
Absence of Staphylococcus aureus (1 g) 
Absence of Salmonella (10 g) 
Not more than 102 Enterobacteriaceae and certain other 
gram-negative bacteria (1 g) 
Cutaneous use 10
2 101 
Absence of Staphylococcus aureus (1 g) 
Absence of Pseudomonas aeruginosa (1 g) 
Vaginal use 10
2 101 
Absence of Staphylococcus aureus (1 g) 
Absence of Pseudomonas aeruginosa (1 g) 
Absence of Candida albicans (1 g) 
TAMC= Total aerobic microbial counts, TYMC= Total yeast and mold counts  
 
MATERIALS & METHODS 
Sample Collection 
A total of 18 pharmaceutical samples were obtained from the 
market and analyzed for microbial limit test and qualitative 
evaluation of objectionable microorganism. The samples 
included were different brands of nine active pharmaceutical 
ingredients and had different form of packaging. All purchased 
items were manufactured by companies registered in India and 
their drugs approved by the Central Drugs Standard Control 
Organization (CDSCO). For each sample (brand), 3 packs with 
different batch numbers were obtained. Each obtained sample 
was examined for the details specified on the package label, 
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including the quantity of active ingredients, the date of 
manufacture, the expiry date and the lot number. 
Sample preparation 
Ten gm of sample to be examined was taken aseptically and 
dissolved or diluted in 100 mL of soybean casein digest 
medium (SCDM).   
Determination of total viable bacteria and fungi 
The prepared samples were immediately filtered in the 0.45 μm 
double membrane filtration assembly. The membrane filters 
was then rinsed with 200 mL of buffer sodium chloride peptone 
solution pH 7.0. One of the membrane filters was kept at the 
surface of Soyabean casein agar (SCDA) for the enumeration 
of total aerobic microbial count (TAMC) and another to the 
surface of Sabouraud dextrose agar (SDA) with an antibiotic 
for determination of fungal number and yeasts. The agar 
medium for bacteria incubated at 320C for 18-24 hr, and the 
plate of agar medium for fungi at 250C for five days. 
Arithmetic average of the count was taken and the number of 
colony forming unit (CFU) per g was calculated [8]. 
Isolation of Microorganism 
From the dilution of 10-3 of each sample, 0.1 ml of suspension 
was spread onto the membrane fecal coliform (MFC) agar, 
MacConkey agar, mannitol salt agar (MSA), and cetrimide agar 
for the isolation and quantification of total fecal coliform, 
Escherichia coli, Klebsiella spp., Staphylococcus spp., and 
Pseudomonas spp., consecutively. MFC agar plates were 
incubated at 44.5 ºC for 18-24 hours, while the other plates 
were incubated at 37 ºC for 24 hours [8].  
 
Table 2: Microbial count of studied non sterile solid dosage form 
Sample Active ingredients Packaging TAMC (CFU/g) TYMC(CFU/g) 
1 Paracetamol Blister ND ND 
2 Paracetamol Alu-Alu 1.0 X 10
1 ND 
3 Nimesulide +  Paracetamol Blister ND ND 
4 Nimesulide +  Paracetamol Alu-Alu ND ND 
5 Aceclofenac + Paracetamol Blister 3.0 X 10
1 1.0  
6 Aceclofenac + Paracetamol Alu-Alu 8.0 X 10
1 2.5  
7 Metformin Blister 1.5 X 10
1 ND 
8 Metformin Alu-Alu ND ND 
9 Lovastatin Blister ND ND 
10 Lovastatin Alu-Alu ND 6.0  
11 Multivitamin with minerals Blister 1.35X 10
2 7.0  
12 Multivitamin with minerals Alu-Alu 8.0 X 10
1 4.0  
13 Multivitamin with herbal ingredient Blister 1.05 X 10
4 8.0  
14 Multivitamin with herbal ingredient Alu-Alu 1.78 X 10
4 1.8 X 101 
15 Calcium with vit.D3 Blister 5.1 X 10
1 2.6 X 101 
16 Calcium with vit.D3 Alu-Alu 3.5 X 10
1 ND 
17 Antacid capsule Blister 1.2 X 10
2 3.0 
18 Antacid capsule Alu-Alu 9.0 X 10
1 5.0 
TAMC= Total aerobic microbial counts, TYMC= Total yeast and mold counts  
 
Identification of isolates 
Purified bacterial colonies recovered from contaminated 
samples were identified according to the diagnostic tables 
given by Barrow & Feltham. Tests performed for this purpose 
include Gram reaction, shape, carbohydrate utilization, catalase 
production, oxidase test, Indole production, spore formation, 
methyl red, Voges Proskauer, nitrate reduction, starch 
hydrolysis, tryptophan hydrolysis, hydrogen sulfide production, 
and citrate utilization [9]. 
 
Statistical analysis 
The data were analyzed by GraphPad version 7.0 statistical 
software. According to the nature of data, two independent 
samples T-test or paired samples were used. T-test was used for 
Journal of Applied Pharmaceutical Research 6(1); 2018: 01 – 06  Khanna et. al  
 
 
  Journal of Applied Pharmaceutical Research (JOAPR)| January – March 2018 | Volume 6 Issue 1 |   4 
statistical comparisons. The differences among the mean values 
were found to be significant at P ≤ 0.05. 
 
RESULTS & DISCUSSIONS  
Non sterile pharmaceuticals, regardless of their dosage form 
and route of administration, must meet the microbiological 
purity criteria set out in an appropriate edition of the 
pharmacopeia. The control of pharmaceuticals is a preventive 
method to prevent the release of harmful products into the 
consumer market. Many microorganism or, more specifically, 
the metabolites they produce, have the ability to degrade or 
inactivate the active ingredients. In addition, the drugs are 
administered by people whose immunity is compromised, so 
that to avoid drug-induced infections, consecutive editions of 
the Pharmacopoeia impose limits on microbial contamination 
[1].  
Table 3: Microbial contaminants isolated from studied samples. 
S. 
No 
Active ingredients Packaging E. coli 
P. 
aeruginosa 
S. 
aureus 
Salmonella 
spp 
Clostridia 
spp 
1 Paracetamol Blister N N N N N 
2 Paracetamol Alu-Alu N N N Y N 
3 Nimesulide +  Paracetamol Blister N N N N N 
4 Nimesulide +  Paracetamol Alu-Alu N N N N N 
5 Aceclofenac + Paracetamol Blister N N Y N N 
6 Aceclofenac + Paracetamol Alu-Alu N Y Y N y 
7 Metformin Blister N N N Y N 
8 Metformin Alu-Alu N N N N N 
9 Lovastatin Blister N N N N N 
10 Lovastatin Alu-Alu N N N N N 
11 Multivitamin with minerals Blister N Y N N N 
12 Multivitamin with minerals Alu-Alu N N N Y N 
13 Multivitamin with herbal ingredient Blister N Y N N Y 
14 Multivitamin with herbal ingredient Alu-Alu N Y N N Y 
15 Vitamin D3 Soft gel Capsule Blister N N N Y N 
16 Vitamin D3 Soft gel Capsule Bottle N N N N Y 
17 Antacid granule Sachet N N Y N N 
18 Antacid granule Bottle N N N N Y 
Y= Present, N= Absent 
T o ta l= 2 1
P .a e ru g in o s a
S . a u re u s
S a lm o n e lla  sp p
U n id e n tif ie d  b a c te r ia
C lo s tr id ia  s p p
U n id e n tif ie d  b a c te r ia
 
Figure 1: Extent of bacterial isolate from solid dosage form 
 
A total of 18 samples of solid pharmaceutical dosage form 
packaged in different primary packaging system were tested. 
The sub groups of the primary packaging system were blister 
and Alu-Alu. Formulation containing raw materials of natural 
source also included: accounted for 11.11% (n=2) of tested 
sample. The detailed analysis of the outcome obtained, non-
compliance and their prevalence is shown in missiles 2 and 3. 
The results indicated that 72.22 % (n=13) of samples had 
shown microbial growth. The obtain outcome showed that 16 
% (n=3) of samples were non-compliant. The samples 
presented no complaints with the EP criteria because of: 
excessive microbial criteria.Sample containing herbal 
ingredients were the most heavily contaminated, showing a 
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bacterial load > 104 CFU/g. A study by Yasir Mehmood et. al 
(2017) showed that 76 % of sample had microbial count out of 
the normal range, during microbial count of tablets in blister 
pack sold in Pakistan [10]. Qasem M Abu Shaqra et al (2014) 
conducted a study on the microbial load of blister pack tablets 
in community pharmacies in Jordan. They acquired a total of 
66 samples of 22 different brands of tablets packed in blister 
packs from community pharmacies in Amman. Out of 66 
items, forty eight (72.7 %) products were free from microbial 
contamination, while 11 (16.7 %) harbored bacteria in counts < 
102 CFU/g. The remaining 7 (10.6 %) items contained counts 
between 102 and < 103 CFU/g [11]. 
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Figure 2:  TAMC of solid dosage form in two different 
packages 
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Figure 3:  TYMC of solid dosage form in two different 
packages 
 
Likewise for yeast and mould, about 88.88 % (n=16) of 
samples contained less than 10 CFU/g viable fungi. TYMC 
outcome indicated that only 5.55 % (n=1) of sample had count 
more than 10 2 CFU/g. According to specification of EU (Table 
1), only one sample exceeded the specified limits.  
The results of detailed microbial evaluation are shown in table 
3 and figure 1. The result showed that all the tested samples 
were free from E.Coli. The microorganism P.aeruginosa, 
Staph. aureus, Salmonella spp and Clostridia spp were found 
in about 22.22 % (n=4), 16.66 % (n=3), 22.22 % (n=4) and 
27.77 % (n=5) respectively. But these microorganisms were 
within acceptable criteria. Some studies on the microbial count 
of tablet confirmed presence of E.Coli.  Various microorganism 
such as Staphylococcus aureus, Pseudomonas aeruginosa, 
Aspergillus species and Penicillium species were isolated from 
solid dosage form in different studies [5,10,12]. The most 
common causes of contamination may be water, person 
handling the product, improper handling, surroundings and the 
storage procedures [4]. 
 
The comparison between two primary blister and Alu-Alu 
packaging system for solid dosage form was presented in figure 
2. There was no significant difference (p>0.05) in microbial 
load of product, packaged in blister and Alu-Alu. The same 
observation was noted for yeast count in blister and Alu-Alu 
packaging system (p>0.05).   
 
CONCLUSION 
This work has demonstrated the acceptable quality of solid 
dosage form manufactured by Indian pharmaceutical 
companies in relation to microbial count and the isolation of 
specified microorganisms. Quality of solid dosage form 
manufactured by Indian pharmaceutical companies revealed 
good adherence to GMP in the country. The microbiological 
quality of tested products was almost similar and within 
acceptable limit, for both studied packs (Alu-Alu and Blister) 
.Hence, effectiveness of the protection provided by the two 
primary packaging was not significantly different. 
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